264 related articles for article (PubMed ID: 21847362)
1. Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer.
Wang YW; Tu PH; Lin KT; Lin SC; Ko JY; Jou YS
Neoplasia; 2011 Aug; 13(8):704-15. PubMed ID: 21847362
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
3. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
Takezawa K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
Clin Cancer Res; 2011 Apr; 17(8):2140-8. PubMed ID: 21415216
[TBL] [Abstract][Full Text] [Related]
4. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T
Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586
[TBL] [Abstract][Full Text] [Related]
5. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
6. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA
Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641
[TBL] [Abstract][Full Text] [Related]
7. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
8. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
9. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
Caumont C; Veillon R; Gros A; Laharanne E; Bégueret H; Merlio JP
Lung Cancer; 2016 Feb; 92():15-8. PubMed ID: 26775590
[TBL] [Abstract][Full Text] [Related]
11. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
12. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
[TBL] [Abstract][Full Text] [Related]
13. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
15. Exosomes from Irradiated Nonsmall Cell Lung Cancer Cells Reduced Sensitivity of Recipient Cells to Anaplastic Lymphoma Kinase Inhibitors.
Wu H; Zeng C; Ye Y; Liu J; Mu Z; Xie Y; Chen B; Nong Q; Wu D
Mol Pharm; 2018 May; 15(5):1892-1900. PubMed ID: 29595984
[TBL] [Abstract][Full Text] [Related]
16. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
17. RAS signaling in ALK fusion lung cancer.
Hrustanovic G; Bivona TG
Small GTPases; 2016; 7(1):32-3. PubMed ID: 26901483
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression.
Vishwamitra D; Li Y; Wilson D; Manshouri R; Curry CV; Shi B; Tang XM; Sheehan AM; Wistuba II; Shi P; Amin HM
Am J Pathol; 2012 May; 180(5):1772-80. PubMed ID: 22414602
[TBL] [Abstract][Full Text] [Related]
20. ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.
Possidente L; Landriscina M; Patitucci G; Borgia L; Lalinga V; Vita G
Med Oncol; 2017 May; 34(5):76. PubMed ID: 28364271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
